Association between plasma Netrin-1 levels and motor and nonmotor symptoms in Parkinson's disease.

Autor: Hua Y; Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China.; Department of Neurology, Wuxi No. 2 People's Hospital, Jiangnan University Medical Center, Wuxi, China., Wang M; Department of Pharmacology, Neuroprotective Drug Discovery Center of Nanjing Medical University, Nanjing Medical University, Nanjing, China., Yao Q; Department of Neurology, Wuxi No. 2 People's Hospital, Jiangnan University Medical Center, Wuxi, China., Hu B; Department of Neurology, Wuxi No. 2 People's Hospital, Jiangnan University Medical Center, Wuxi, China., Lu F; Department of Neurology, Wuxi No. 2 People's Hospital, Jiangnan University Medical Center, Wuxi, China., Fan Y; Department of Pharmacology, Neuroprotective Drug Discovery Center of Nanjing Medical University, Nanjing Medical University, Nanjing, China., Lu W; Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Jazyk: angličtina
Zdroj: CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Sep; Vol. 30 (9), pp. e70022.
DOI: 10.1111/cns.70022
Abstrakt: Background: Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by dopaminergic neuron degeneration and diverse motor and nonmotor symptoms. Early diagnosis and intervention are crucial but challenging due to reliance on clinical presentation. Recent research suggests potential biomarkers for early detection, including plasma netrin-1 (NTN-1), a protein implicated in neuronal survival.
Methods: This cross-sectional study recruited 105 PD patients and 65 healthy controls, assessing plasma NTN-1 levels and correlating them with clinical characteristics. Statistical analyses explored associations between NTN-1 levels and PD symptoms, considering demographic factors.
Results: PD patients exhibited significantly lower plasma NTN-1 levels compared to controls. NTN-1 demonstrated moderate potential as a PD biomarker. Positive correlations were found between NTN-1 levels and motor, depression, and cognitive symptoms. Multiple regression analysis revealed disease duration and NTN-1 levels as key factors influencing symptom severity. Gender also impacted symptom scores.
Conclusion: Reduced plasma NTN-1 levels correlate with PD severity, suggesting its potential as a biomarker. However, further research is needed to elucidate the roles of NTN-1 in PD pathophysiology and validate its diagnostic and therapeutic implications. Understanding the involvement of NTN-1 may lead to personalized management strategies for PD.
(© 2024 The Author(s). CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje